Pronóstico del mercado de servicios de farmacocinética de Asia Pacífico hasta 2031: análisis regional, por tipo de fármaco (moléculas pequeñas, moléculas grandes y vacunas), tipo de servicio (estudios preclínicos de ADME y humanos, análisis y generación de informes de PK/PD, simulaciones de dosificación, análisis de riesgos y otros), aplicación terapéutica (oncología, enfermedades infecciosas, trastornos neurológicos, enfermedades autoinmunes, trastornos ginecológicos, enfermedades cardiovasculares, trastornos respiratorios y otros) y usuario final (empresas farmacéuticas y de biotecnología, organizaciones de investigación por contrato y otros)
La creciente adopción de modelos in vivo e in vitro para comprender la variabilidad en la farmacocinética impulsa el mercado de servicios farmacocinéticos de Asia Pacífico
La recopilación y el manejo de enormes datos farmacocinéticos generados durante la fabricación de medicamentos son tareas costosas, tediosas y que requieren mucho tiempo. La naturaleza intensiva en mano de obra y costos de estas tareas resalta la necesidad de modelos como los modelos de simulación farmacocinética y los modelos de correlación farmacocinética in vitro-in vivo (IVIVC) para la predicción de parámetros farmacocinéticos. El modelo de simulación farmacocinética es una herramienta que interpreta la cinética de los medicamentos en el entorno vital en condiciones específicas utilizando modelos computacionales y matemáticos. Además, el modelo IVIVC es una parte fundamental del proceso de descubrimiento de fármacos. Analizar las predicciones PK/PD en las primeras etapas del desarrollo de fármacos es necesario para las estrategias de optimización de los fármacos y también para reducir aún más las tasas de deserción. Se han producido avances significativos en el desarrollo de nuevas estrategias in vitro e in vivo para mejorar y caracterizar las propiedades farmacocinéticas. Los modelos IVIVC se están proponiendo como una alternativa rentable para evaluar las propiedades biofarmacéuticas que analizan la biodisponibilidad de los fármacos y su aplicación. Por lo tanto, se prevé que dichos modelos in vivo e in vitro proporcionen oportunidades lucrativas para el mercado de servicios farmacocinéticos de Asia Pacífico en el futuro cercano.
Descripción general del mercado de servicios farmacocinéticos de Asia Pacífico
El crecimiento del mercado de servicios farmacocinéticos de Asia Pacífico en China se atribuye principalmente al mercado farmacéutico establecido, al aumento de los gastos de I+D de las empresas farmacéuticas y biofarmacéuticas, al aumento del número de ensayos clínicos debido a los menores costos operativos y a las políticas regulatorias favorables vigentes. Según el informe de la EFPIA publicado en 2023, el gasto en I+D de las empresas farmacéuticas en China creció de 10.814,23 millones de dólares en 2020 a 12.989,23 millones de dólares en 2021. China tiene el segundo mercado farmacéutico más grande del mundo. La excesiva población del país, junto con un aumento de los casos de diversas enfermedades no transmisibles e infecciosas, alimenta la necesidad de nuevas moléculas de fármacos, lo que convierte a China en un mercado principal en Asia Pacífico.
Ingresos y pronóstico del mercado de servicios de farmacocinética de Asia Pacífico hasta 2031 (millones de dólares estadounidenses)
Segmentación del mercado de servicios de farmacocinética de Asia Pacífico
El mercado de servicios de farmacocinética de Asia Pacífico se clasifica en tipo de fármaco, tipo de servicio, aplicación terapéutica, usuario final y país.
Según el tipo de fármaco, el mercado de servicios de farmacocinética de Asia Pacífico se segmenta en moléculas pequeñas, moléculas grandes y vacunas. El segmento de moléculas pequeñas tuvo la mayor participación de mercado en 2023.
En términos de tipo de servicio, el mercado de servicios farmacocinéticos de Asia Pacífico se clasifica en estudios preclínicos ADME y humanos, análisis e informes PK/PD, simulaciones de dosificación, análisis de riesgos y otros. El segmento de estudios preclínicos ADME y humanos tuvo la mayor participación de mercado en 2023.
Por aplicación terapéutica, el mercado de servicios farmacocinéticos de Asia Pacífico se segmenta en oncología, enfermedades infecciosas, trastornos neurológicos, enfermedades autoinmunes, trastornos ginecológicos, enfermedades cardiovasculares, trastornos respiratorios y otros. El segmento de oncología tuvo la mayor participación de mercado en 2023.
Por usuario final, el mercado de servicios farmacocinéticos de Asia Pacífico se segmenta en empresas farmacéuticas y biotecnológicas, organizaciones de investigación por contrato y otros. El segmento de organizaciones de investigación por contrato tuvo la mayor participación de mercado en 2023.
Por país, el mercado de servicios farmacocinéticos de Asia Pacífico está segmentado en China, Japón, India, Australia, Corea del Sur y el resto de Asia Pacífico. Japón dominó la participación de mercado de servicios farmacocinéticos de Asia Pacífico en 2023.
Allucent; Certara Inc.; Charles River Laboratories International Inc; Eurofins Scientific SE; PACIFIC BIOLABS; Parexel International Corp; SGS SA; Shanghai Medicilon Inc.; y Thermo Fisher Scientific Inc. son algunas de las empresas líderes que operan en el mercado de servicios farmacocinéticos de Asia Pacífico.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Asia Pacific Analysis
5.1 Asia Pacific Pharmacokinetics Services Market Overview
5.2 Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Asia Pacific Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Asia Pacific Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Asia Pacific Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Asia Pacific Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Asia Pacific Pharmacokinetics Services Market - Country Analysis
10.1 Asia Pacific
10.1.1 Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.5 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.3 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.5.4 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.5.5 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.5.6 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.6.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Shanghai Medicilon Inc.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Asia Pacific Pharmacokinetics Services Market Segmentation
Table 2. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. R&D Expenditure of Indian Companies, 2018-2020 (US$ Million)
Table 11. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 12. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 13. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 14. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 15. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 16. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 17. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 18. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 19. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 20. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 21. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 22. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 23. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 24. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 25. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 26. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 27. Glossary of Terms
?
List of Figures
Figure 1. Asia Pacific Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Asia Pacific Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Asia Pacific Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Asia Pacific Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Asia Pacific Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Asia Pacific Pharmacokinetics Services Market - Revenue by Key Countries 2023 (US$ Million)
Figure 29. Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 31. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 33. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 34. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 35. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Shanghai Medicilon Inc.
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.